| Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer | Science advances | | | 2025 | 92 | 212 |
|
| Acceptability of an Electronic Patient-Reported Outcomes-Based Model of Care to Monitor Symptoms Related to Cancer Treatment with Immune Checkpoint Inhibitors : Results from the IePRO Randomized Controlled Trial | Seminars in oncology nursing | | | 2025 | 6 | 37 |
|
| Convergent inducers and effectors of T cell paralysis in the tumour microenvironment | Nature reviews. Cancer | | | 2025 | 61 | 0 |
|
| Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy : results of SAKK 11/16, a phase IIa trial | Experimental hematology & oncology | | | 2025 | 60 | 58 |
|
| The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition | npj precision oncology | | | 2024 | 82 | 33 |
|
| Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy | Cell | | | 2024 | 994 | 349 |
|
| Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma | Science immunology | | | 2024 | 291 | 0 |
|
| SwissDock 2024: major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina | Nucleic acids research | | | 2024 | 9 | 447 |
|
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | | 2023 | 126 | 148 |
|
| Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18 F-FDG PET/CT and Confirmed by Biopsy | Clinical nuclear medicine | | | 2023 | 3 | 0 |
|
| Testing a model of care for patients on immune checkpoint inhibitors based on electronic patient-reported outcomes : protocol for a randomized phase II controlled trial | JMIR research protocols | | | 2023 | 126 | 222 |
|
| Neoadjuvant immunotherapy : a promising new standard of care | International journal of molecular sciences | | | 2023 | 109 | 502 |
|
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | | 2023 | 102 | 98 |
|
| Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma | International journal of molecular sciences | | | 2023 | 12 | 24 |
|
| Dendritic cells direct circadian anti-tumour immune responses | Nature | | | 2023 | 799 | 221 |
|
| Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient | Cancer biology & therapy | | | 2023 | 100 | 91 |
|
| Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts : Implications for Adjuvant Treatment | Journal of clinical oncology | | | 2022 | 6 | 33 |
|
| Towards a national strategy for digital pathology in Switzerland | Virchows Archiv | | | 2022 | 245 | 176 |
|
| Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma : a retrospective multicentre analysis | European journal of cancer | | | 2022 | 4 | 0 |
|
| Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer : a joint analysis of OnCovid and ESMO-CoCARE registries | Journal for immunotherapy of cancer | | | 2022 | 9 | 14 |
|
| Perspectives in Melanoma : meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy) | Journal of translational medicine | | | 2022 | 9 | 37 |
|
| Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors | European journal of cancer | | | 2022 | 13 | 103 |
|
| Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies | Journal for immunotherapy of cancer | | | 2022 | 3 | 9 |
|
| Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma | Journal for immunotherapy of cancer | | | 2022 | 6 | 8 |
|
| Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma | Cancers | | | 2022 | 3 | 50 |
|
| An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves | Cancers | | | 2022 | 3 | 7 |
|
| COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE) | ESMO open | | | 2022 | 3 | 6 |
|
| Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations : A Case Study in Advanced Melanoma | MDM policy & practice | | | 2022 | 6 | 34 |
|
| Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer : A joint analysis of OnCovid and ESMO-CoCARE registries | ESMO Immuno-Oncology Congress 2022 | | | 2022 | 9 | 8 |
|
| The SwissSimilarity 2021 Web Tool : Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience | International journal of molecular sciences | | | 2022 | 4 | 99 |
|
| Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital | JCO clinical cancer informatics | | | 2022 | 4 | 14 |
|
| Structure-based prediction of BRAF mutation classes using machine-learning approaches | Scientific reports | | | 2022 | 10 | 9 |
|
| Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening | Cancers | | | 2022 | 3 | 38 |
|
| SwissBioisostere 2021 : updated structural, bioactivity and physicochemical data delivered by a reshaped web interface | Nucleic acids research | | | 2022 | 4 | 79 |
|
| Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events | Journal for immunotherapy of cancer | | | 2022 | 5 | 24 |
|
| Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors | Journal of enzyme inhibition and medicinal chemistry | | | 2022 | 5 | 177 |
|
| Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma | Journal for immunotherapy of cancer | | | 2022 | 4 | 56 |
|
| Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response | European journal of cancer | | | 2021 | 3 | 26 |
|
| 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis | Journal for immunotherapy of cancer | | | 2021 | 5 | 8 |
|
| Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany | Journal for immunotherapy of cancer | | | 2021 | 3 | 71 |
|
| Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy | European journal of cancer | | | 2021 | 3 | 0 |
|
| Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab | Gynecologic Oncology Reports | | | 2021 | 266 | 134 |
|
| Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply | Lancet oncology | | | 2021 | 7 | 0 |
|
| Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors : A Delphi study | European journal of cancer | | | 2021 | 4 | 85 |
|
| Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases | European journal of cancer | | | 2021 | 4 | 44 |
|
| Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors | Cancer treatment reviews | | | 2021 | 4 | 33 |
|
| Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy : a multicentre, retrospective, cohort study | Lancet oncology | | | 2021 | 17 | 0 |
|
| Acute cardiac manifestations under immune checkpoint inhibitors — beware of the obvious : a case report | European heart journal. Case reports | | | 2021 | 11 | 8 |
|
| Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity | Cancer discovery | | | 2021 | 7 | 8 |
|
| Swiss-PO : a new tool to analyze the impact of mutations on protein three-dimensional structures for precision oncology | npj precision oncology | | | 2021 | 5 | 1 |
|
| Cystathionine-gamma-lyase overexpression in T cells enhances antitumor effect independently of cysteine autonomy | Cancer science | | | 2021 | 9 | 31 |
|
| Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma | Annals of oncology | | | 2021 | 4 | 54 |
|
| Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1) | Journal of medicinal chemistry | | | 2021 | 3 | 64 |
|
| Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors | Journal of medicinal chemistry | | | 2021 | 5 | 162 |
|
| First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver | The Journal of nuclear medicine | | | 2020 | 5 | 43 |
|
| Evolving impact of long-term survival results on metastatic melanoma treatment | Journal for immunotherapy of cancer | | | 2020 | 4 | 28 |
|
| The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019 | Journal of translational medicine | | | 2020 | 10 | 8 |
|
| Comparison of the clinical utility of two different size next generation sequencing (NGS) gene panels for solid tumours | Molecular Analysis for Precision Oncology (MAP) Virtual Congress 2020 | | | 2020 | 4 | 22 |
|
| Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma : First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM | 30. Deutschen Hautkrebskongresses (ADO-Jahrestagung) | | | 2020 | 5 | 7 |
|
| Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology | International journal of molecular sciences | | | 2020 | 5 | 10 |
|
| Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives | British journal of cancer | | | 2020 | 12 | 7 |
|
| Integrating radiomics into holomics for personalised oncology : from algorithms to bedside | European radiology experimental | | | 2020 | 3 | 32 |
|
| Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment : The TERAVOLT Experience | Cancer cell | | | 2020 | 4 | 13 |
|
| Managing cancer patients during the COVID-19 pandemic : an ESMO multidisciplinary expert consensus | Annals of oncology | | | 2020 | 5 | 28 |
|
| ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee | Annals of oncology | | | 2020 | 4 | 5 |
|
| Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes | Journal for immunotherapy of cancer | | | 2020 | 9 | 23 |
|
| Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis | Annals of oncology | | | 2020 | 3 | 28 |
|
| Herpes simplex encephalitis in adult patients with MASP-2 deficiency | PLOS pathogens | | | 2019 | 8 | 8 |
|
| Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With CD274/PD-L1 Amplification | JCO precision oncology | | | 2019 | 3 | 0 |
|
| MedCo : Enabling Secure and Privacy-Preserving Exploration of Distributed Clinical and Genomic Data | IEEE/ACM transactions on computational biology and bioinformatics | | | 2019 | 3 | 0 |
|
| Adverse effects of immune-checkpoint inhibitors : epidemiology, management and surveillance | Nature reviews. Clinical oncology | | | 2019 | 5 | 0 |
|
| Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy) | Journal of translational medicine | | | 2019 | 10 | 6 |
|
| Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer | Science translational medicine | | | 2018 | 3 | 0 |
|
| Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer | Nature communications | | | 2018 | 9 | 47 |
|
| ECCO essential requirements for quality cancer care : Melanoma | Critical reviews in oncology/hematology | | | 2018 | 4 | 19 |
|
| Practice-Changing Developments in Stage III Melanoma : Surgery, Adjuvant Targeted Therapy, and Immunotherapy | American Society of Clinical Oncology educational book | | | 2018 | 3 | 26 |
|
| Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma | European journal of cancer | | | 2018 | 3 | 0 |
|
| Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma | Blood | | | 2018 | 4 | 36 |
|
| Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma | Haematologica | | | 2018 | 10 | 5 |
|
| ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors) | Clinical microbiology and infection | | | 2018 | 8 | 56 |
|
| Autoimmune Colitis in Patients Undergoing Therapy with Immune Checkpoint Inhibitors : a Case Series | Annual Meeting Swiss Society of Gastroenterology (SGG-SSG), Swiss Society of Visceral Surgery (SGVC-SSCV), Swiss Association for the Study of the Liver (SASL,) Swiss Society of Endoscopy Nurses and Associates (SVEP-ASPE) | | | 2018 | 3 | 25 |
|
| T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus | European Journal of Immunology | | | 2018 | 6 | 32 |
|
| A severe case of neuro-Sjögren's syndrome induced by pembrolizumab | Journal for immunotherapy of cancer | | | 2018 | 8 | 28 |
|
| CD73 expression and clinical significance in human metastatic melanoma | Oncotarget | | | 2018 | 7 | 8 |
|
| A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ) | 32nd ASCO Annual Meeting | | | 2017 | 8 | 13 |
|
| Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors | Cancer immunology and immunotherapy | | | 2017 | 3 | 24 |
|
| Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma | Science translational medicine | | | 2017 | 6 | 0 |
|
| SwissADME : a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules | Scientific reports | | | 2017 | 8 | 241 |
|
| Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma | Cancer immunology and immunotherapy | | | 2016 | 3 | 37 |
|
| Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma | Melanoma and immunotherapy bridge 2015 | | | 2016 | 4 | 3 |
|
| Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma : a phase I, open-label, single-arm study | 16th World Congress on Cancers of the Skin | | | 2016 | 5 | 4 |
|
| ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016 | Annals of oncology | | | 2016 | 3 | 41 |
|
| Attracting cavities for docking. Replacing the rough energy landscape of the protein by a smooth attracting landscape | Journal of computational chemistry | | | 2016 | 4 | 79 |
|
| 1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2) | Bioorganic & medicinal chemistry letters | | | 2016 | 7 | 0 |
|
| Genomic analysis reveals novel drivers and progression pathways in skin basal cell carcinoma | Human genome meeting 2016 | | | 2016 | 7 | 12 |
|
| Gaining momentum : New options and opportunities for the treatment of advanced melanoma | Cancer treatment reviews | | | 2015 | 3 | 0 |
|
| Preface | Immuno-Oncology | | | 2015 | 4 | 6 |
|
| Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope | 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) | | | 2015 | 3 | 14 |
|
| Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma | European Cancer Congress 2015 | | | 2015 | 9 | 0 |
|
| Immuno-Oncology | | | | 2015 | 4 | 18 |
|
| Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients | 2015 ASCO Annual Meeting | | | 2015 | 3 | 7 |
|
| Triple wild type melanoma profiling in the Caris Molecular IntelligenceTM registry | European Cancer Congress (ECC 2015) | | | 2015 | 4 | 0 |
|
| Triple wild type melanoma profiling in the Caris Molecular Intelligence registry | 51st Annual meeting of the American Society of Clinical Oncology (ASCO) | | | 2015 | 7 | 15 |
|
| A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) | 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) | | | 2015 | 4 | 24 |
|
| Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases : final results of an open-label pilot study | European journal of cancer | | | 2014 | 5 | 0 |
|
| MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion : results of a Phase I trial | Journal of translational medicine | | | 2014 | 3 | 29 |
|
| Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors | European journal of medicinal chemistry | | | 2014 | 3 | 0 |
|
| FcgRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via Ipilimumab-dependent ADCC in melanoma patients | Society for Immunotherapy of Cancer : 29th Annual Meeting | | | 2014 | 3 | 31 |
|
| Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab | Cancer immunology and immunotherapy | | | 2014 | 4 | 29 |
|
| The Peroxisomal Enzyme L-PBE Is Required to Prevent the Dietary Toxicity of Medium-Chain Fatty Acids | Cell Reports | | | 2013 | 278 | 130 |
|
| Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships | PloS one | | | 2013 | 4 | 29 |
|
| Shaping the interaction landscape of bioactive molecules | Bioinformatics | | | 2013 | 9 | 32 |
|
| A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I : Is EGFR TKI resistance predictable ? | Lung cancer | | | 2013 | 4 | 0 |
|
| Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients | PloS one | | | 2013 | 6 | 38 |
|
| Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib | Lung cancer | | | 2013 | 3 | 0 |
|
| Nano‐particle vaccination combined with TLR ‐7 and ‐9 ligands triggers memory and effector CD 8 + T ‐cell responses in melanoma patients | European Journal of Immunology | | | 2012 | 5 | 14 |
|
| Expanding molecular modeling and design tools to non‐natural sidechains | Journal of computational chemistry | | | 2012 | 3 | 0 |
|
| Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells | International journal of cancer | | | 2012 | 7 | 0 |
|
| Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07 | Oncology Reports | | | 2012 | 3 | 27 |
|
| Defining and searching for structural motifs using DeepView/Swiss-PdbViewer | BMC bioinformatics | | | 2012 | 6 | 7 |
|
| Identification of human IKK-2 inhibitors of natural origin (Part II) : In Silico prediction of IKK-2 inhibitors in natural extracts with known anti-inflammatory activity | European journal of medicinal chemistry | | | 2011 | 4 | 0 |
|
| Unique spectrum of activity of prosimian TRIM5alpha against exogenous and endogenous retroviruses | Journal of virology | | | 2011 | 7 | 31 |
|
| Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities | Journal of virology | | | 2011 | 8 | 8 |
|
| Identification of human IKK-2 inhibitors of natural origin (part I) : modeling of the IKK-2 kinase domain, virtual screening and activity assays | PloS one | | | 2011 | 4 | 10 |
|
| Rational design of indoleamine 2,3-dioxygenase inhibitors | Journal of medicinal chemistry | | | 2010 | 3 | 0 |
|
| Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function | The Journal of immunology | | | 2010 | 4 | 0 |
|
| Frequent MAGE mutations in human melanoma | PloS one | | | 2010 | 6 | 29 |
|
| Use of the FACTS solvation model for protein-ligand docking calculations. Application to EADock | JMR. Journal of molecular recognition | | | 2010 | 4 | 0 |
|
| Foreword Preface to the JMR Special Issue on ‘Dynamic Aspects of Molecular Recognition’ | JMR. Journal of molecular recognition | | | 2010 | 4 | 12 |
|
| MM-GBSA binding free energy decomposition and T cell receptor engineering | JMR. Journal of molecular recognition | | | 2010 | 4 | 0 |
|
| Fourier transform convolution integrals applied to generalized Born molecular volume | Journal of computational chemistry | | | 2010 | 4 | 0 |
|
| A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide | The Journal of immunology | | | 2007 | 5 | 0 |
|
| T cell recognition of hapten. Anatomy of T cell receptor binding of a H-2kd-associated photoreactive peptide derivative | The Journal of biological chemistry | | | 1999 | 8 | 84 |
|
